The
View from Here
Renee Arnold
The pharmaceutical industry is often at odds about how best to use pharmacoeconomic
analyses as evidence for drug pricing, government reimbursement, formulary
inclusion and compound novelty...
Read
more...
Upcoming Issues
Issue 3/March '07
Nanotechnology
Issue 4/April '07
Chemoinformatics
Issue 5/May '07
Molecular
imaging as biomarker
|
A
review of 2006
|
| |
Top
Reviews |
 |
New
breath for rotavirus vaccines
Parashar,
U, Bresee, JS, Widdowson, M-A, Gentsch, JR
Drug Discov Today: Therapeutic Strategies
New
vaccines against rotavirus, the leading cause of severe childhood
gastroenteritis worldwide, are on the threshold of introduction
into immunization programs in affluent nations. A reduction of the
health burden and costs of severe rotavirus disease in these countries
should be evident within 2–3 years of vaccine introduction...
|
| |
Targeting
therapy in psoriatic arthritis
Mease, PJ
Drug Discovery Today: Therapeutic Strategies
Recent
trials with emerging biologic agents, especially anti-TNF agents,
in patients with psoriatic arthritis have shown excellent results
in their ability to improve symptoms and signs of both joint and
skin disease. Also, for the first time, inhibition of disease progression,
as measured radiographically, has been demonstrated....
|
| |
Developing
a paradigm of drug innovation: an evaluation algorithm
Caprino, L, Russo, P
Drug Discovery Today
Assessment
of drug innovation is a burning issue because it involves so many
different perspectives, mainly those of patients, decision- and
policy-makers, regulatory authorities and pharmaceutical companies...
|
|
| |
Abstracts
of Key Research Articles
How
much will Herceptin really cost?
Barett, A, Roques, T, Small, M, Smith RD
BMJ. 2006; 333(7578):1118-1120.
Cost-effectiveness
of HIV treatment in resource-poor settings - the case of Cote
d'Ivoire
Goldie, SJ, Yazdanpanah, Y, Losina, E, Weinstein, MC, Anglaret,
X, Walensky, RP, Hsu, HE, Kimmel, A, Holmes, C, Kaplan, JE, Freedberg,
KA.
N Engl J Med. 2006; 355(11): 1141-1153.
Long-term
cost effectiveness of early and sustained dual oral antiplatelet
therapy with clopidogrel given for up to one year after percutaneous
coronary intervention results: from the Clopidogrel for the Reduction
of Events During Observation (CREDO) trial
Beinart, SC, Kolm, P, Veledar, E, Zhang, Z, Mahoney, EM, Bouin,
O, Gabriel, S, Jackson, J, Chen, R, Caro, J, Steinhubl, S, Topol,
E, Weintraub, WS
J Am Coll Cardiol. 2005; 46(5):761-9.
Cardiovascular
disease prevention with a multidrug regimen in the developing
world: a cost-effectiveness analysis
Gaziano, TA, Opie, LH, Weinstein, MC
Lancet 2006; 368(9536):679-686.
Comparative
efficacy and safety of low-dose fluticasone propionate and montelukast
in children with persistent asthma
Ostrom, NK, Decotiis, BA, Lincourt, WR, Edwards, LD, Hanson, KM,
Carranza Rosenzweig, JR, Crim, C
J Pediatr. 2005; 147(2): 213-220.
Narrative
review: drug-eluting stents for the management of restenosis:
a critical appraisal of the evidence
Tung, R, Kaul, S, Diamond, GA, Shah, PK
Ann Intern Med. 2006; 144(12):913-919.
The
cost-effectiveness of argatroban treatment in heparin-induced
thrombocytopenia: the effect of early versus delayed treatment
Arnold, RJ, Kim, R, Tang, B
Cardiol Rev. 2006; 14(1): 7-13.
Clinical
and economic outcomes of oral linezolid versus intravenous vancomycin
in the treatment of MRSA-complicated, lower-extremity skin and
soft-tissue infections caused by methicillin-resistant Staphylococcus
aureus
Sharpe, JN, Shively, EH, Polk, HC Jr
Am J Surg. 2005; 189(4): 425-428.
Cost-effectiveness
of prophylactic low molecular weight heparin in pregnant women
with a prior history of venous thromboembolism
Johnston, JA, Brill-Edwards, P, Ginsberg, JS, Pauker, G, Eckman,
MH
Am J Med. 2005; 118(5): 503-14.
Clinical
implications of chemotherapy-induced diarrhea in patients with
cancer
Arnold, RJ, Gabrail, N, Raut, M, Kim, R, Sung, JC, Zhou, Y
J Support Oncol. 2005; 3(3):227-232.
|
|
